For intractable diseases like Parkinson's, the IGI takes an 'end-to-end' approach: building better disease models, discovering root causes, and simultaneously exploring multiple treatment modalities like direct CRISPR edits, cell therapies, and microbiome interventions. This tackles the entire problem, not just one piece.

The next wave of blockbuster therapies will likely be platforms addressing upstream, root-cause systems like chronic inflammation or metabolic health. This approach targets the interconnected nature of the body, influencing multiple diseases simultaneously and shifting away from the traditional single-disease treatment model.

Instead of the traditional 'disease-target-drug' approach, Soleil finds compounds that create a desired cellular change first. Only after identifying a promising, well-tolerated molecule with a known cellular mechanism do they use bioinformatics to determine which disease and patient population it's best suited for.

Instead of targeting individual gene mutations in diseases like ALS, condensate science focuses on shared cellular structures where genetic risks converge. This approach creates a broader therapeutic target, potentially treating more patients with diverse genetic profiles.

The company's foundational insight is that cellular stress is a central mechanism in vastly different diseases. In cancer, they increase stress to kill cells; in degenerative conditions like Parkinson's or hair loss, they aim to decrease stress to restore function. This unifying principle allows their single platform to tackle a diverse therapeutic portfolio.

Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.

Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.

Haya's approach redefines the drug target. Instead of focusing on single proteins or pathways, they identify the "causal unit" of disease as the cellular behaviors that dictate how patients feel, function, and survive, and then work backwards to find a target.

Beyond brains, research labs are now growing three-dimensional human uteruses from scratch. This breakthrough provides an unprecedented model to study the aging of the female reproductive system and test therapies aimed at extending fertility, potentially even after menopause.